CannBioRx Life Sciences Corp (ATNFW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CannBioRx Life Sciences Corp (ATNFW) has a cash flow conversion efficiency ratio of -0.210x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.13 Million) by net assets ($5.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ATNFW net asset quality score to measure how much of total assets are equity-financed.
CannBioRx Life Sciences Corp - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how CannBioRx Life Sciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is CannBioRx Life Sciences Corp's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CannBioRx Life Sciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CannBioRx Life Sciences Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
An Pha Petroleum Group JSC
VN:ASP
|
N/A |
|
Polyplex (Thailand) Public Company Limited
F:PKW
|
0.014x |
|
Gujarat Raffia Industries Limited
NSE:GUJRAFFIA
|
0.123x |
|
Mirriad Advertising PLC
LSE:MIRI
|
-1.322x |
|
Binh Dinh Minerals JSC
VN:BMC
|
N/A |
|
Tipco Asphalt Public Company Limited
F:TPY1
|
0.122x |
|
NURAN WIRELESS INC.
F:1RNA
|
N/A |
|
Adamas One Corp. Common Stock
NASDAQ:JEWL
|
0.097x |
Annual Cash Flow Conversion Efficiency for CannBioRx Life Sciences Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of CannBioRx Life Sciences Corp from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see ATNFW market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.25 Million | $-1.48 Million | -0.160x | -100.19% |
| 2023-12-31 | $-127.73K | $-10.92 Million | 85.508x | +8098.28% |
| 2022-12-31 | $11.34 Million | $-12.13 Million | -1.069x | -985.73% |
| 2021-12-31 | $39.32 Million | $-3.87 Million | -0.098x | +22.98% |
| 2020-12-31 | $30.29 Million | $-3.87 Million | -0.128x | -48.58% |
| 2019-12-31 | $38.57 Million | $-3.32 Million | -0.086x | -1141.34% |
| 2018-12-31 | $113.87 Million | $-789.23K | -0.007x | -57.23% |
| 2017-12-31 | $112.83 Million | $-497.36K | -0.004x | -- |
About CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more